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ABSTRACT
Background: Endometriosis and interstitial cystitis/pain-
ful bladder syndrome share similar symptoms. Interstitial
cystitis was once considered rare, but it is now recognized
as more common than previously thought. This review
examines evidence that patients presenting with symp-
toms typically attributed to endometriosis or with unre-
solved pelvic pain after treatment for endometriosis may,
in fact, have interstitial cystitis, and suggests approaches
for appropriate diagnosis.
Methods: A MedLine search using “chronic pelvic pain,”
“endometriosis,” “interstitial cystitis,” and “bladder origin
pain” as key words was performed for the most recent
English-language articles. Additional references were ob-
tained through cross-referencing the bibliography cited in
each publication.
Discussion: The symptoms of endometriosis and inter-
stitial cystitis frequently overlap, and these 2 conditions
may even coexist in the same patient. In cases of unre-
solved endometriosis and persistent pelvic pain, patients
may have interstitial cystitis. A variety of tools are available
to aid in identifying interstitial cystitis.
Conclusion: Gynecologists should be alert to the possi-
ble presence of interstitial cystitis in patients who present
with chronic pelvic pain typical of endometriosis.
Key Words: Chronic pelvic pain, Endometriosis, Intersti-
tial cystitis, Bladder origin pain.
INTRODUCTION
Endometriosis and interstitial cystitis (IC) are common
causes of chronic pelvic pain (CPP) in women.1–6 Chronic
pelvic pain is commonly defined as noncyclic pain lasting
for 6 months or longer and whose severity leads to med-
ical care or functional disability. Chronic pelvic pain ac-
counts for approximately 10% of referrals to gynecology
practices, 12% of hysterectomies, and more than 40% of
gynecologic diagnostic laparoscopies.1,7–11 However, de-
termining the origins of CPP is often challenging because
many conditions can cause pelvic pain. A complicating
factor is that patients with CPP often have more than one
disorder that might cause pain.1,7,12,13 To optimize patient
outcomes, it is important to identify and treat all potential
causes of CPP.
Endometriosis, a common cause of CPP, is diagnosed in
up to 80% of patients with CPP.2–5 However, increasing
evidence suggests that IC is more prevalent than was
previously thought and may play a significant role in the
cause of CPP.6 The importance of considering the urinary
bladder as a source of pain was emphasized in a study at
a regional center specializing in CPP that investigated the
prevalence of IC in patients who experienced persistent or
recurrent pelvic pain after undergoing a hysterectomy for
CPP. Of the 111 patients enrolled, 88 (79%) were diag-
nosed with bladder dysfunction consistent with IC.14 This
diagnosis was based on positive findings from one or both
cystoscopy and a potassium sensitivity test (PST), a pro-
cedure that may identify patients with abnormal bladder
epithelial permeability.15 A positive PST finding has been
demonstrated in approximately 80% of patients with
IC.15,16 The results of this study indicate that IC should be
considered in all patients who present with CPP, even
those previously diagnosed with other conditions such as
endometriosis. Patients with unresolved or refractory CPP
should be given an evaluation for IC as well, preferably
before any invasive surgical procedure.
Other clinical studies also have indicated that many
women who present with CPP may have IC, and that IC
and endometriosis are often concurrent conditions in the
same patient.17–20 A multicenter study by Parsons et al17 in
3 US gynecology practices found that among 134 patients
presenting with pelvic pain, 114 (85%) had a positive PST,
The Urogynecology Center, Overland Park, Kansas and Kansas University Medical
Center, Kansas City, Kansas, USA.
Dr Butrick has received grant/research support from Astellas Pharma and Urigen
and serves on the advisory board and speakers’ bureau of Ortho-McNeil Pharma-
ceutical. Article supported by Ortho Women’s Health & Urology, a division of
Ortho-McNeil Pharmaceutical, Inc.
Address reprint requests to: Charles Butrick, MD, The Urogynecology Center, 12200
West 106th St, Ste 130, Overland Park, KS 66215, USA. Telephone: 913 307 0044;
Fax: 913 227 0094; E-mail: CButrick@aol.com.
© 2007 by JSLS, Journal of the Society of Laparoendoscopic Surgeons. Published by
the Society of Laparoendoscopic Surgeons, Inc.
JSLS (2007)11:182–189 182
SCIENTIFIC PAPERwhich suggests that their pain may have had a bladder
component. These results provide further support for gy-
necologists to give greater weight to IC than in the past in
the differential diagnosis of pelvic pain.17 Early identifica-
tion of IC in patients with CPP may also result in better
treatment outcomes.
OVERVIEW OF ENDOMETRIOSIS
Symptoms commonly associated with endometriosis in-
clude perimenstrual lower abdominal pain and dyspareu-
nia.2 However, patients with endometriosis can also
present with dysuria, hematuria, urinary frequency, and
painful voiding, particularly if the bladder is involved.2,21
Patients with endometriosis may have no symptoms at all,
and the pain typically ascribed to endometriosis often has
little correlation with the location or extent of the dis-
ease.2,22 Therefore, the clinician should consider other
causes of pain, even if endometriosis is diagnosed.
Endometriosis is defined as the presence and growth of
endometrial mucosa, glands, and stroma outside of the
uterus.2 Common sites of implantation include the ova-
ries, uterosacral ligaments, cul-de-sac, and the uterovesi-
cal peritoneum.21,22 As with the normal uterine endome-
trium, these extrauterine implants remain under the cyclic
influence of ovarian hormones, and are stimulated to
grow and then break down with each menstrual cycle.22
Pain is caused by inflammation that results from cyclic
sloughing of these endometrial glands, by the release of
neurokinins, and by pressure and traction on surrounding
tissue from adhesions, if they are present.
Endometriosis is suspected based on the patient’s history
and physical examination, and confirmed by histologic
findings from laparoscopic-guided biopsy. It is essential to
ask about symptoms like dyspareunia and urinary urgen-
cy/frequency. During the physical examination, the phy-
sician may detect tender nodules and masses in the pelvic
region, a tender retroverted uterus, or implants in utero-
sacral ligaments. Visualization of lesions by laparoscopy,
with confirmation by biopsy, is considered the “gold stan-
dard” for diagnosis.2 Evidence increasingly suggests that
biopsy is required to confirm the diagnosis of endometri-
osis.22 In a study by Walter et al23 that investigated the
accuracy of laparoscopic visualization alone in making a
diagnosis, only 49% (67/138) of sites that appeared visu-
ally positive for endometriosis had positive histology on
biopsy. Findings responsible for the false-positives in-
cluded endosalpingiosis, malignancies, carbon deposits
from previous ablations, and other abnormalities, as well
as normal peritoneum.23
Optimal approaches to the management of endometriosis
are determined by many factors, including either or both
the patient’s desire for fertility augmentation and pain
relief, the patient’s age, and the stage of disease. The
approach can be pharmacologic, surgical, or a combina-
tion of both. Analgesic therapy with nonsteroidal antiin-
flammatory agents is appropriate for the patient with mild,
premenstrual endometriosis-related pain.22,24 The goals of
hormone therapy are to interrupt the growth of endome-
trial tissue implants by suppressing estrogen production
or to promote the atrophy of such implants through pro-
gestational agents, or both of these. Combined estrogen-
progestin oral contraceptives (OCs) are generally consid-
ered first-line hormone therapy. Low-dose, continuous,
monophasic OC regimens (versus intermittent OC regi-
mens) appear to be effective for suppressing endometrial
growth. Other therapies that may be used include proges-
tational agents like medroxyprogesterone acetate and nor-
ethindrone acetate, the weak androgen danazol, and go-
nadotropin-releasing (GnRH) agonists like leuprolide,
nafarelin, or goserelin.22,24 It is important to note that
suppressive hormone therapies, such as GnRH agonists
and OCs, also may have beneficial effects for patients with
IC, irritable bowel syndrome, and almost any pain disor-
der that is associated with perimenstrual symptom
flares.25,26 Therefore, pain relief on suppressive hormone
therapy does not necessarily equate with a diagnosis of
endometriosis, or even the presence of a gynecologic
disorder.
Pharmacologic therapy often succeeds in suppressing
pain symptoms and halting the progression of endometri-
osis. However, once treatment is discontinued, endome-
triosis will commonly become active again. For women
with moderate or severe endometriosis whose symptoms
are unrelieved by pharmacologic treatment, or for women
who are older, surgery may be the most appropriate
therapy. Conservative surgery attempts to eradicate visual
signs of endometriosis and adhesions, eliminate symp-
toms of CPP, and restore the pelvic anatomy to a normal
condition.22 However, because surgery cannot eliminate
all microscopic endometrial implants, the disease may
progress and symptoms may recur. For women with se-
vere persistent endometriosis, the only treatment option
may be a hysterectomy with bilateral salpingo-oophorec-
tomy.
OVERVIEW OF IC
Patients with IC may present with a range of symptoms,
including pelvic or suprapubic pain, urinary urgency/
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most characteristic symptom of IC.28 Approximately 15%
of patients with IC first present with pain in the absence of
urologic symptoms.27 Dyspareunia is not uncommon, and
symptoms often flare after sexual intercourse.29 Symptoms
are also affected by the menstrual cycle and may become
more pronounced before the onset of menstruation.28,30
The term interstitial cystitis/painful bladder syndrome (IC/
PBS) is intended to encompass a broader symptomatic
definition,31–33 and is recognized by the National Institute
of Diabetes and Digestive and Kidney Diseases.33
The pathogenesis of IC is not clearly understood; how-
ever, several hypotheses have been advanced to account
for the condition. One of the most widely accepted theo-
ries suggests that the bladder urothelium is defective. The
inner wall of the bladder is covered by a glycosaminogly-
can-containing mucous layer. This layer protects the blad-
der by preventing infectious organisms from adhering to
the epithelium and by prohibiting the entrance of irritating
urinary solutes into the interstitium.34 In patients with IC,
this protective layer is defective, allowing solutes like
urinary potassium to penetrate or leak into the mucosal
layer.15 This can lead to activation of C-fibers, release of
substance P, and mast cell degranulation, causing further
injury and triggering the symptoms of urinary urgency/
frequency and pelvic pain.30
Given the similarities between endometriosis and IC—
nonspecific symptomatology, as well as pain in the ab-
sence of other symptoms—it is critical that gynecologists
consider IC as a diagnostic possibility when a patient
initially presents with symptoms of CPP. Endometriosis is
frequently asymptomatic.22 Even if endometriosis is con-
firmed by biopsy in a patient with CPP, it should not be
assumed to be the only cause of pain, because it is com-
mon for patients with CPP to have multiple pain genera-
tors.
Consider IC in CPP Patients Refractory to
Treatment for Endometriosis
It is not uncommon for endometriosis to recur after sur-
gery; however, this often does not take place for years.
Wheeler and Malinak35 reported on a study of 423 patients
who had undergone conservative surgery for endometri-
osis. The annual rate of recurrence for biopsy-confirmed
endometriosis ranged from only 0.9% in the first postop-
erative year to 13.6% in the eighth year.35 Therefore, if
symptoms recur within the first 12 months after surgical
therapy, IC should be considered as a possible cause and
recurrent endometriosis is unlikely.
When therapy for the symptoms of endometriosis is un-
successful, increasing evidence suggests that IC may be an
underlying cause. Interstitial cystitis may be the sole cause
of symptoms, or occur concurrently with other causes
such as endometriosis or myofascial pain. In one study by
Clemons et al,18 45 women scheduled to undergo diag-
nostic laparoscopy for CPP were also evaluated with cys-
toscopy. Interstitial cystitis was diagnosed in 17 (38%)
patients and endometriosis in 21 (47%). Of the 21 patients
diagnosed with endometriosis, 7 (33%) also had IC.18
In a separate study conducted by Chung et al19 at a
regional center specializing in CPP, 178 women present-
ing with chronic pelvic pain and uterine and bladder/
anterior vaginal wall pain upon physical examination
were evaluated using both laparoscopic and cystoscopic
procedures.19 Irritative voiding symptoms were reported
by 145 (81%) patients. Laparoscopy confirmed that 134
(75%) patients had biopsy-proven endometriosis, and cys-
toscopy confirmed that 159 (89%) had IC (Table 1). Both
endometriosis and IC were diagnosed in 115 (65%) pa-
tients.19
Similar results were reported in a study by Paulson and
Delgado20 Of 35 women with CPP who underwent lapa-
roscopy and cystoscopy with hydrodistension, 28 (80%)
had IC; 28 (80%) had endometriosis; 24 (69%) had both
diseases concurrently; and 32 (91%) had diagnoses of
either IC, endometriosis, or both (Table 2).20 The majority
of patients (61%) complained of lower urinary tract symp-
toms in addition to pelvic pain.
Although the rates of IC in these studies vary widely, they
indicate that many women with CPP may have IC alone or
concurrently with endometriosis. No known causal rela-
tionship exists between endometriosis and IC, in part
because the origin of both conditions is poorly under-
stood. It is speculated that both diseases are caused by
autoimmune disorders, with an unknown factor acting as
a trigger for one or both.20 Another possible explanation is
Table 1.
Pathology Among 178 Patients Chronic Pelvic Pain19
Pathology Number Percentage
Interstitial cystitis (IC) 159 89%
Endometriosis 134 75%
IC and endometriosis 115 65%
IC alone 44 25%
Endometriosis alone 19 11%
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mation and viscerovisceral hyperalgesia, in which chronic
noxious stimuli at one site can contribute to referred pain
and inflammation at other visceral organs.6,20,36 Pelvic
organ cross-talk is important in the various functions of
the pelvic organs (eg, storage, elimination, and sexual
function), yet when alterations in these neural pathways
as a result of disease or injury occur, these shared path-
ways result in pelvic organ cross-sensitization. This ex-
plains why patients often have multiple CPP disorders
simultaneously (eg, IC, inflammatory bowel disease (IBS),
vulvodynia, or dysmenorrhea). This concept of viscero-
visceral cross-sensitization has repeatedly been demon-




As noted, IC can be difficult to distinguish from disorders
like endometriosis.25 Gynecologists, who see more
women with CPP than other specialists, should be aware
of the symptom overlap between IC and endometriosis
and should screen patients with pelvic pain for IC.25 When
a patient presents with symptoms typically attributed to
endometriosis, or with unresolved endometriosis, the fol-
lowing diagnostic approach may help determine whether
IC is a contributing factor.
History and Physical Examination
A thorough history and physical examination are critical
for an evaluation of any patient who presents with CPP.
During the history, it is important to ask about the onset of
symptoms and the extent and location of the pain (in IC,
pain usually worsens as the bladder fills and improves
after voiding). Details on voiding symptoms, such as ur-
gency, hesitancy, and/or frequency, should be deter-
mined as well.30
A physical examination should be performed to evaluate
for tenderness and to determine whether the tenderness
elicited reproduces the pain that the patient typically ex-
periences.1 In patients with IC, a pelvic examination will
often reveal tenderness of the bladder base, even upon
gentle palpation.28 A commonly overlooked finding in
patients with CPP is levator muscle spasm and its associ-
ated myofascial pain.38 The examination should also rule
out vaginitis and other pelvic pathology.28
A urinalysis and urine culture should be performed to
detect the presence of infection or hematuria. Patients
with IC may also have a concurrent bladder infection that
requires diagnosis and treatment.28,39 Additional tests such
as a urine cytology may be helpful in excluding other
potential diagnoses (ie, bladder cancer or carcinoma in
situ).28
Symptom screening tools are useful because they can
quantify behaviors that are associated with IC. They can
also identify symptoms like dyspareunia that patients
might not associate with their bladder symptoms and
therefore may not report. A 24-hour voiding diary should
be used to assess urinary frequency, nocturia, and fluid
intake.28 Healthy patients average 6.5 voids per day,
whereas patients diagnosed with IC may on average ex-
perience 16.5 voids daily.30 Voided volume is also impor-
tant. Normal volume is 240mL to 300mL; an urge to void at
120mL or less should be considered abnormal.
The Pelvic Pain and Urgency/Frequency (PUF) patient
symptom scale is a questionnaire that screens for urinary
urgency/frequency behaviors associated with IC, as well
as pelvic pain and dyspareunia.40 Studies show that PUF
scores correlate with the likelihood of a positive PST,
which is an indicator of IC.40,41
Tests such as the PST and intravesical anesthetic challenge
are being used with increasing frequency to help establish
a diagnosis of IC.17,42 The PST involves instillation first of
sterile water, and then of a potassium chloride solution
into the bladder to assess evoked symptoms of pain and
urgency. Patients without IC should not experience these
symptoms in response to either solution. In contrast, ap-
proximately 80% of patients with IC have a positive re-
sponse to instillation of the potassium chloride solu-
tion.15,16 Intravesical instillation of an anesthetic solution is
Table 2.
Pathology of 35 Patients With Chronic Pelvic Pain20
Pathology Number Percentage
Interstitial cystitis (IC) 28 80%
Endometriosis 28 80%
IC and endometriosis 24 69%
IC or endometriosis* 32 91%
Adhesions 11 30%
Other pathology† 3 9%
*Includes patients with only one condition or with both.
†2 patients had an ovarian cyst, and 1 had ovarian remnant
syndrome. Adapted with permission from Paulson JD, Delgado
M. Chronic Pelvic Pain: the Occurrence of Interstitial Cystitis in a
Gynecological Population. JSLS. 2005;9:426–430.
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abates, often for a few days, it can be assumed that the
bladder is its source. Most patients with IC have a positive
response to this anesthetic challenge test, which suggests
that it may be a useful diagnostic tool for IC.42
Cystoscopy with hydrodistension of the bladder with the
patient under general or conduction anesthesia is another
tool to aid in the diagnosis of IC. Hydrodistension of an IC
bladder may reveal glomerulations or Hunner’s ulcers, as
well as decreased bladder capacity.28 However, these
findings are not required for the diagnosis of IC. Hunner’s
ulcers are seen in approximately 4% of women with IC,43
and many patients with symptoms consistent with IC have
a negative cystoscopy.44 Glomerulations have also been
observed upon hydrodistension in asymptomatic women
undergoing tubal ligation.43,45 Thus, false-negatives and
false-positives are seen with cystoscopy. Cystoscopy may
be necessary to rule out bladder cancer in patients who
have gross or microscopic hematuria, are over 40 years
old, have a history of tobacco use, or have occupational or
other risk factors.36,43 In addition to its diagnostic value,
hydrodistension has been shown to improve the symp-
toms of IC in 30% to 60% of patients, with relief lasting for
up to several months.28,30
MANAGING THE PATIENT WITH IC
Most experts in IC use a multimodal approach to therapy.
In addition to pharmacologic agents, patients will often
benefit from nonpharmacologic approaches, such as diet
modification and physical therapy.
Pharmacologic Approaches
Pentosan polysulfate sodium (PPS) (ELMIRON, Ortho-Mc-
Neil Pharmaceutical, Inc, Raritan, NJ) is the only oral
therapy approved by the Food and Drug Administration
(FDA) for the relief of bladder pain or discomfort associ-
ated with IC.46,47 This agent is a heparin-like compound
similar in chemical structure to naturally occurring glycos-
aminoglycans and is believed to reinforce the protective
mucosal lining of the bladder, thereby preventing irritants
from entering the interstitium. Pentosan polysulfate so-
dium may also inhibit mast cell degranulation.46 It has
been proven effective for symptom relief in multiple stud-
ies.47–51 The recommended dose of PPS is 100mg tid taken
1 hour before or 2 hours after meals. Some patients ex-
perience reduced symptoms within 4 weeks52; however,
others may require 3 to 6 months of therapy to notice an
improvement in symptoms.47 Generally, the longer the
patient has symptoms, the longer it may take for these
symptoms to resolve. Pentosan polysulfate sodium is well
tolerated. In clinical trials, the most frequently reported
side effects in subjects taking recommended doses of PPS
were blood in the stool (6.3%), diarrhea (4%), nausea
(4%), hair loss (4%), headache (3%), rash (3%), upset
stomach (2%), abdominal pain (2%), liver function abnor-
malities (1%), and dizziness (1%).
Dimethyl sulfoxide (DMSO), an antiinflammatory analge-
sic with muscle relaxant properties, is the only FDA-
approved bladder instillation therapy for IC. Although its
mechanism of action is not known, DMSO is thought to
increase bladder capacity, inhibit mast cell degranulation,
and modulate neural activity in the bladder.46 Instillation
therapy with DMSO can be administered every 1 to 2
weeks in cycles of 6 to 8 weeks. Patients comfortable with
self-catheterization can perform this procedure at home,
as needed.46 Dimethyl sulfoxide is well tolerated but may
leave a garlic-like taste and odor on the patient’s breath
and skin for up to 3 days after treatment. Blood tests,
including liver function and kidney function, should be
performed every 6 months.46 Several trials have demon-
strated that DMSO can provide moderate relief of symp-
toms, as well as increase bladder capacity for many pa-
tients with IC.46,53–55
Various adjunctive therapies can be prescribed, as
needed, to help provide relief from pain and other symp-
toms associated with IC, although these agents are not
FDA approved for use in this patient population. Tricyclic
antidepressants such as amitriptyline may be useful in IC.
These drugs inhibit the secretion of histamine and block
the reuptake of norepinephrine and serotonin in both the
peripheral and central nervous system, which helps to
mitigate pain. In addition, amitriptyline has anticholin-
ergic effects that reduce urinary frequency and sedative
effects that help with sleep disturbances and reduce noc-
turia.36
Other therapies reported to be useful include antihista-
mines such as hydroxyzine and anticonvulsants such as
gabapentin.36
Nonpharmacologic Approaches
Strong anecdotal evidence suggests that diet modification
offers some benefit to patients with IC. The elimination of
certain foods may help to control symptoms and avoid
flare-ups of the disease. Foods to avoid include chocolate,
caffeine, spicy foods, and foods high in acidity, including
tomatoes and citrus fruits and juices. Artificial sweeteners
and cigarette smoking also appear to exacerbate symp-
toms of IC. Food diaries can help to identify foods and
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tolerated.46,56
Patients with IC should attempt to improve their lifestyle,
exercise, and use stress-reduction strategies, all of which
are thought to contribute to a better overall quality of
life.57 Bladder training may also be of value. Patients with
IC can be taught to schedule voids, gradually increasing
the time interval to 3 to 4 hours.46
CONCLUSION
Patients with CPP may have endometriosis, IC, or both.
Because the symptoms of these diseases overlap consid-
erably, gynecologists should focus on the bladder as a
potential source of symptoms. Any patient who presents
with pelvic pain or has unresolved “endometriosis pain”
should be evaluated for IC. Successful management of
patients with CPP must involve the identification of all
pain generators. If endometriosis is found, the clinician
must still look for additional causes of visceral pain. Pain
control is more likely to occur when all sources of pain are
treated, including IC, irritable bowel syndrome, myofas-
cial pain, and vulvodynia. Gynecologists can successfully
manage CPP by screening for IC-related symptoms, mak-
ing an early diagnosis, and initiating appropriate therapy
and follow-up.
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